CTL epitope analogs

A peptide selected from group consisting of SEQ ID NO:

• 38, 52 and 64′ produced according to the steps of:
• (a) providing a sequence of a human-cytomegalovirus-cytotoxic-T-lymphocyte epitope and a combinatorial peptide library which contains peptide analogs of said viral-cytotoxic-T-lymphocyte epitope;
• (b) screening said combinatorial peptide library for immunogenicity;
• (c) analyzing the results of said screening to select one or more peptide analogs which may have improved immunogenicity relative to the native human-cytomegalovirus-cytotoxic-T-lymphocyte epitope;
• (d) assaying said one or more peptide analogs for immunogenicity;
• (e) analyzing the results of the assay in step (d);
• (f) selecting one or more highly immunogenic peptide analogs based on the analysis of step (e);
• (g) assaying said highly immunogenic peptide analogs for broad recognition of MHC allele subtypes;
• (h) analyzing the results of the assay in step (g);
• (i) selecting one or more highly immunogenic peptide analogs with retained breadth of recognition of MHC allele subtypes relative to the native human-cytomegalovirus-cytotoxic-T-lymphocyte epitoPe based on the analysis of the earlier steps;
• and
• (j) synthesizing the peptide selected in step (i) wherein said peptide is selected from the group consisting of SEQ ID NOS:
• 38, 52 and 64′ wherein said peptide is selected from the group consistin of SEQ ID NOS:
• 38, 52 and 64.